NASDAQ:ZFGN - Zafgen Stock Price, Forecast & News

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Zafgen Inc (NASDAQ:ZFGN) issued its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.03. View Zafgen's Earnings History.

Zafgen is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zafgen.

7 equities research analysts have issued twelve-month price objectives for Zafgen's stock. Their forecasts range from $0.78 to $17.00. On average, they anticipate Zafgen's stock price to reach $7.06 in the next twelve months. This suggests a possible upside of 478.7% from the stock's current price. View Analyst Price Targets for Zafgen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zafgen.

Headlines about ZFGN stock have trended somewhat positive on Friday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zafgen earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Zafgen.

Zafgen saw a decrease in short interest in December. As of December 31st, there was short interest totalling 520,800 shares, a decrease of 9.8% from the December 15th total of 577,500 shares. Based on an average trading volume of 687,800 shares, the short-interest ratio is presently 0.8 days. Currently, 1.6% of the shares of the stock are sold short. View Zafgen's Current Options Chain.

Some companies that are related to Zafgen include Ovid Therapeutics (OVID), Arcturus Therapeutics (ARCT), Aravive (ARAV), Kala Pharmaceuticals (KALA), Harrow Health (HROW), Akorn (AKRX), Aldeyra Therapeutics (ALDX), Agile Therapeutics (AGRX), Obseva (OBSV), PhaseBio Pharmaceuticals (PHAS), NuCana (NCNA), Spero Therapeutics (SPRO), Galectin Therapeutics (GALT), ContraFect (CFRX) and TAIWAN LIPOSOME/S (TLC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), TG Therapeutics (TGTX), BlackRock (BLK), Micron Technology (MU), Energy Transfer LP Unit (ET), Fate Therapeutics (FATE), SCYNEXIS (SCYX), Esperion Therapeutics (ESPR) and Lexicon Pharmaceuticals (LXRX).

Zafgen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.23%). View Institutional Ownership Trends for Zafgen.

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Zafgen.

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZFGN stock can currently be purchased for approximately $1.22.

Zafgen has a market capitalization of $45.60 million. The biopharmaceutical company earns $-61,370,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 38 workers across the globe.View Additional Information About Zafgen.

The official website for Zafgen is http://www.zafgen.com/.

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]